BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Panzitt K, Zollner G, Marschall H, Wagner M. Recent advances on FXR-targeting therapeutics. Molecular and Cellular Endocrinology 2022. [DOI: 10.1016/j.mce.2022.111678] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Finamore C, Festa C, Fiorillo B, Leva FSD, Roselli R, Marchianò S, Biagioli M, Spinelli L, Fiorucci S, Limongelli V, Zampella A, De Marino S. Expanding the Library of 1,2,4-Oxadiazole Derivatives: Discovery of New Farnesoid X Receptor (FXR) Antagonists/Pregnane X Receptor (PXR) Agonists. Molecules 2023;28:2840. [PMID: 36985811 DOI: 10.3390/molecules28062840] [Reference Citation Analysis]
2 Aseem SO, Hylemon PB, Zhou H. Bile Acids and Biliary Fibrosis. Cells 2023;12. [PMID: 36899928 DOI: 10.3390/cells12050792] [Reference Citation Analysis]
3 Dvořák Z, Li H, Mani S. Microbial Metabolites as Ligands to Xenobiotic Receptors: Chemical Mimicry as Potential Drugs of the Future. Drug Metab Dispos 2023;51:219-27. [PMID: 36184080 DOI: 10.1124/dmd.122.000860] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Di Tommaso N, Santopaolo F, Gasbarrini A, Ponziani FR. The Gut-Vascular Barrier as a New Protagonist in Intestinal and Extraintestinal Diseases. Int J Mol Sci 2023;24. [PMID: 36674986 DOI: 10.3390/ijms24021470] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Larabi AB, Masson HLP, Bäumler AJ. Bile acids as modulators of gut microbiota composition and function. Gut Microbes 2023;15:2172671. [PMID: 36740850 DOI: 10.1080/19490976.2023.2172671] [Reference Citation Analysis]
6 Di Ciaula A, Bonfrate L, Baj J, Khalil M, Garruti G, Stellaard F, Wang HH, Wang DQ, Portincasa P. Recent Advances in the Digestive, Metabolic and Therapeutic Effects of Farnesoid X Receptor and Fibroblast Growth Factor 19: From Cholesterol to Bile Acid Signaling. Nutrients 2022;14. [PMID: 36500979 DOI: 10.3390/nu14234950] [Reference Citation Analysis]
7 Fang J, Yu C, Li X, Yao J, Fang Z, Yoon S, Yu W. Gut dysbiosis in nonalcoholic fatty liver disease: pathogenesis, diagnosis, and therapeutic implications. Front Cell Infect Microbiol 2022;12. [DOI: 10.3389/fcimb.2022.997018] [Reference Citation Analysis]
8 Nguyen JT, Shaw RPH, Anakk S. Bile Acids-A Peek Into Their History and Signaling. Endocrinology 2022;163. [PMID: 36130324 DOI: 10.1210/endocr/bqac155] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
9 Huang YH, Wu YH, Tang HY, Chen ST, Wang CC, Ho WJ, Lin YH, Liu GH, Lin PY, Lo CJ, Yeh YM, Cheng ML. Gut Microbiota and Bile Acids Mediate the Clinical Benefits of YH1 in Male Patients with Type 2 Diabetes Mellitus: A Pilot Observational Study. Pharmaceutics 2022;14:1857. [PMID: 36145605 DOI: 10.3390/pharmaceutics14091857] [Reference Citation Analysis]
10 Zhang S, Zhou J, Wu W, Zhu Y, Liu X. The Role of Bile Acids in Cardiovascular Diseases: from Mechanisms to Clinical Implications. Aging and disease 2022. [DOI: 10.14336/ad.2022.0817] [Reference Citation Analysis]